Ocular safety of chronic use of sildenafil citrate in treatment of pulmonary arterial hypertension: data from phase III study and open label extension

Source: BMJ
Area: News
Selective phosphodiesterase type 5 inhibitors are capable of crossing the blood-retina barrier. Concerns have been raised about potential ocular side effects of sildenafil; the most common visual disturbance reported is a dose dependent reversible impairment of colour discrimination, principally in the blue-green to blue-purple range. Studies of the effects of sildenafil on ocular vasculature have not had consistent results. To evaluate potential effects on visual function and the ocular safety profile of sildenafil during chronic oral use, a placebo controlled trial in pulmonary arterial hypertension (PAH) (Read more...)

Full Story →